Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. by Rhee, Soo-Yon et al.
Rhee, SY; Varghese, V; Holmes, SP; Van Zyl, GU; Steegen, K; Boyd,
MA; Cooper, DA; Nsanzimana, S; Saravanan, S; Charpentier, C; de
Oliveira, T; Etiebet, MA; Garcia, F; Goedhals, D; Gomes, P; Gn-
thard, HF; Hamers, RL; Hoffmann, CJ; Hunt, G; Jiamsakul, A;
Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Marconi, VC;
D’amour Ndahimana, J; Ndembi, N; Ngo-Giang-Huong, N; Rokx,
C; Santoro, MM; Schapiro, JM; Schmidt, D; Seu, L; Sigaloff, KCE;
Sirivichayakul, S; Skhosana, L; Sunpath, H; Tang, M; Yang, C; Car-
mona, S; Gupta, RK; Shafer, RW (2017) Mutational Correlates of
Virological Failure in Individuals Receiving a WHO-Recommended
Tenofovir-Containing First-Line Regimen: An International Collab-
oration. EBioMedicine, 18. pp. 225-235. ISSN 2352-3964 DOI:
https://doi.org/10.1016/j.ebiom.2017.03.024
Downloaded from: http://researchonline.lshtm.ac.uk/4649866/
DOI: 10.1016/j.ebiom.2017.03.024
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Research Paper
Mutational Correlates of Virological Failure in Individuals Receiving a
WHO-Recommended Tenofovir-Containing First-Line Regimen: An
International Collaboration
Soo-Yon Rhee a,⁎, Vici Varghese a, Susan P. Holmes b, Gert U. Van Zyl c, Kim Steegen d, Mark A. Boyd e,
David A. Cooper e, Sabin Nsanzimana f, Shanmugam Saravanan g, Charlotte Charpentier h,ah, Tulio de Oliveira i,
Mary-Ann A. Etiebet j, Federico Garcia k, Dominique Goedhals l, Perpetua Gomes m, Huldrych F. Günthard n,
Raph L. Hamers o, Christopher J Hoffmann p, Gillian Hunt q, Awachana Jiamsakul e, Pontiano Kaleebu r,
Phyllis Kanki s, Rami Kantor t, Bernhard Kerschberger u, Vincent C. Marconi v, Jean D'amour Ndahimana f,
Nicaise Ndembi w, Nicole Ngo-Giang-Huong x, Casper Rokx y, Maria M. Santoro z, Jonathan M. Schapiro aa,
Daniel Schmidt ab, Lillian Seu ac, Kim C.E. Sigaloff o, Sunee Sirivichayakul ad, Lindiwe Skhosana d,
Henry Sunpath ae, Michele Tang a, Chunfu Yang af, Sergio Carmona d, Ravindra K. Gupta ag,1, Robert W. Shafer a,1
a Department of Medicine, Stanford University, Stanford, CA 94305, USA
b Department of Statistics, Stanford University, Stanford, CA 94305, USA
c Division of Medical Virology, Stellenbosch University, National Health Laboratory Service, Tygerberg 7505, South Africa
d Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, WITS 2050, South Africa
e The Kirby Institute, UNSW, Sydney, NSW 2052, Australia
f HIV/AIDS Division, Rwanda Biomedical Center, Kigali, P.O. Box 87, Rwanda
g Y.R. Gaitonde Centre for AIDS Research and Education, Voluntary Health Services, Taramani, Chennai 600113, India
h Univ Paris Diderot, Sorbonne Paris Cité, IAME, UMR 1137, INSERM, F-75018 Paris, France
i College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
j Institute of Human Virology, University of Maryland School of Medicine, MD 21201, USA
k Hospital Universitario San Cecilio, 18012 Granada, Spain
l Department of Medical Microbiology and Virology, National Health Laboratory Service/University of the Free State, Bloemfontein 9301,South Africa
m Laboratorio de Virologia, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon 1449-005, Portugal
n University Hospital Zurich, Institute of Medical Virology, University of Zurich, 8091 Zurich, Switzerland
o Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, P.O. Box 22700, The Netherlands
p Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
q National Institute for Communicable Diseases, Sandringham, Johannesburg 2131, South Africa
r Uganda Virus Research Institute, Entebbe, P.O. Box 49, Uganda
s Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
t Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI 02903, USA
u Médecins sans Frontières, Mbabane, H100, Swaziland
v Emory University School of Medicine, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
w Institute of Human Virology Nigeria, Abuja, Federal Capital Territory, P.O. Box 9396, Nigeria
x Institut de Recherche pour le Developpement (IRD), UMI 174 - PHPT, 13572 Marseilles, France
y Department of Internal Medicine and Infectious Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands
z University of Rome Tor Vergata, 00173 Rome, Italy
aa National Hemophilia Center, Sheba Medical Center, Tel Aviv 5262000, Israel
ab Department of Infectious Disease Epidemiology, HIV/AIDS, STI and Blood Born Infections, Robert Koch-Institute, 13353 Berlin, Germany
ac School of Medicine, University of Alabama at Birmingham, AL 35210, USA
ad Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
ae School of Clinical Sciences, University of KwaZulu- Natal, Durban 4041, South Africa
af Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention, Port-au-Prince, Haiti
ag UCL, Department of Infection, London WC1E 6BT, UK
ah AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France
EBioMedicine 18 (2017) 225–235
⁎ Corresponding author at: Division of Infectious Diseases, Lane Building, L-134, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.
E-mail address: syrhee@stanford.edu (S.-Y. Rhee).
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.ebiom.2017.03.024
2352-3964/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.com
a b s t r a c ta r t i c l e i n f o
Article history:
Received 26 January 2017
Received in revised form 7 March 2017
Accepted 17 March 2017
Available online 19 March 2017
Tenofovir disoproxil fumarate (TDF) genotypic resistance deﬁned by K65R/N and/or K70E/Q/G occurs in 20% to
60% of individualswith virological failure (VF) on aWHO-recommended TDF-containingﬁrst-line regimen.How-
ever, the full spectrum of reverse transcriptase (RT)mutations selected in individuals with VF on such a regimen
is not known. To identify TDF regimen-associated mutations (TRAMs), we compared the proportion of each RT
mutation in 2873 individuals with VF on aWHO-recommended ﬁrst-line TDF-containing regimen to its propor-
tion in a cohort of 50,803 antiretroviral-naïve individuals. To identify TRAMs speciﬁcally associatedwith TDF-se-
lection pressure, we compared the proportion of each TRAM to its proportion in a cohort of 5805 individuals with
VF on a ﬁrst-line thymidine analog-containing regimen. We identiﬁed 83 TRAMs including 33 NRTI-associated,
40 NNRTI-associated, and 10 uncommon mutations of uncertain provenance. Of the 33 NRTI-associated
TRAMs, 12–A62V, K65R/N, S68G/N/D, K70E/Q/T, L74I, V75L, andY115F –weremore common among individuals
receiving a ﬁrst-line TDF-containing compared to a ﬁrst-line thymidine analog-containing regimen. These 12
TDF-selected TRAMswill be important for monitoring TDF-associated transmitted drug-resistance and for deter-
mining the extent of reduced TDF susceptibility in individuals with VF on a TDF-containing regimen.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Tenofovir disoproxil fumarate (TDF) plus a cytosine analog is the
universally recommended NRTI backbone for ﬁrst-line antiretroviral
(ARV) therapy and for pre-exposure prophylaxis. TDF is also frequently
recommended for second-line therapy provided it retains activity
against viruses that emerge following virological failure (VF) on a
ﬁrst-line ARV treatment regimen.
We recently performed ameta-analysiswhich showed that between
20% to 60% of individuals with VF on a TDF-containing regimen devel-
oped genotypic evidence of TDF resistance deﬁned as the presence of ei-
ther K65R/N or K70E/G/Q in the HIV-1 reverse transcriptase (RT) gene
(TenoRes Study) (TenoRes Study, 2016). The risk of having TDF resis-
tance at the time of VF was signiﬁcantly higher in low and middle-in-
come countries (LMICs) compared with upper-income countries
(UICs). In addition, having a low baseline CD4 count, receiving
lamivudine (3TC) rather than emtricitabine (FTC), and receiving nevira-
pine (NVP) rather than efavirenz (EFV) were also associated with a risk
of TDF resistance.
It is not known, however, whether K65R/N and K70E/G/Q represent
the full spectrum of NRTI-associated mutations in individuals receiving
aWHO-recommended ﬁrst-line TDF-containing regimen. Therefore, we
analyzed the full set of publicly available RT sequences from studies of
such individuals. To identify TDF regimen-associated mutations
(TRAMs), we compared the proportion of each RT mutation in individ-
uals with VF on a WHO-recommended ﬁrst-line TDF-containing regi-
men with its proportion in a group of ARV-naïve individuals. To
identify TRAMs speciﬁcally associated with TDF-selection pressure, we
compared the proportion of each TRAM with its proportion in a group
of individualswithVF on aﬁrst-line thymidine analog regimen. As resis-
tance mutations are often accompanied by compensatory mutations,
we also determined which combinations of TDF-selected mutations
were likely to co-occur.
2. Materials and Methods
2.1. Individuals and Sequences
WeanalyzedHIV-1 RT sequences and clinical data from studies of in-
dividuals with VF on aWHO-recommended ﬁrst-line regimen compris-
ing TDF plus either 3TC or FTC plus either NVP or EFV. Study inclusion
criteria required that individuals reported being ARV-naïve prior to re-
ceiving ﬁrst-line therapy, that the year and country of virus sampling
were known, and that RT sequences encompassing codons 40 to 240
were available.
Study individuals were from 51 datasets including 29 in the TenoRes
study for which RT sequences were made publicly available (n = 1573
individuals) and 22 additional recently published studies (n= 1840 in-
dividuals) identiﬁed through GenBank HIV-1 sequence submissions
(Supplementary Table 1 and Supplementary Data 1). VF was deﬁned
by local viral load thresholds or surveillance protocols, which was
1000 copies/ml for studies performed in LMICs. Viral load (VL) data,
however, was not routinely made available.
Mutations were deﬁned as amino acid differences at positions 1 to
240 between each sequence and the consensus subtype B amino acid
reference sequence (Rhee et al., 2003). Because of the possibility that
some individuals may have received a thymidine analog before receiv-
ing a TDF-containing regimen, as such switchesmay not have always re-
ported (Gregson et al., 2016),we excluded from our analysis individuals
with sequences containing one or more canonical thymidine analogue
mutations (TAMs) – M41L, D67N, K70R, L210W, T215Y/F, and K219Q/
E (Menendez-Arias, 2011).
Each sequencewas subtyped using the Rega subtyping tool version 3
(Pineda-Pena et al., 2013). Sequence quality control measures were
taken to identify sequences with APOBEC G-to-A hypermutation
(Rhee et al., 2016). To exclude duplicate sequences, we examined the
relatedness of sequences within each study and within the total study
population by creating a neighbor-joining phylogenetic tree using the
HKY85 substitution model with a gamma distribution for variable
sites as implemented by PAUP (Supplementary Data 2).
2.2. Identiﬁcation of TDF-regimen Associated Mutations (TRAMs)
We compared the proportion of each RT mutation with its propor-
tion in a set of sequences from 50,803 ARV-naïve individuals described
in a recent publication (Rhee et al., 2015). The proportion of eachmuta-
tionwas analyzed using Fisher's Exact Test and the p valuewas adjusted
using the Holm's method to control the family-wise error rate for mul-
tiple hypothesis testing (Holm, 1979). Among mutations with an ad-
justed p b 0.05, those that occurred in ≥10 individuals receiving a
TDF-containing regimen and ≥3 times more frequently than in the
ARV-naïve population were classiﬁed as TRAMs. The rationale for re-
quiring that a TRAM occur ≥3 times more commonly in the TDF recipi-
ents was to reduce the risk of false positive associations arising from
differences in the distribution of subtype-dependent polymorphisms
between the TDF recipients and ARV-naïve controls. The rationale for
requiring that a TRAM appear in ≥10 individuals in the TDF group was
to focus on the most commonly occurring TRAMs.
TRAMs were further classiﬁed as to whether they were previously
reported to be at an NRTI-associated drug resistance mutation (DRM)
position, an NNRTI-associated DRM position, an RTI-selected mutation
position not clearly associated with either RTI class, or a position not
previously associated with RTI selection pressure (Rhee et al., 2016).
NRTI-associated DRM positions were referred to as established if they
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were on the IAS-USA DRM list (Wensing et al., 2015). NRTI-associated
DRMs not among the exclusionary TAMs that had been reported to be
selected by thymidine analogs were called non-canonical TAMs
(Gonzales et al., 2003).
To determine whether the proportion of a TRAMwas inﬂuenced by
HIV-1 subtype, we performed a 2 × 5 Chi-square test to compare the
proportion of each TRAM in the ﬁve most common subtypes in our
dataset (A, B, C, G, CRF01_AE). TheHolm's adjustment formultiple com-
parisons (adjusted p b 0.05)was used to identifywhich TRAMs occurred
in signiﬁcantly different proportions in different subtypes. For such
TRAMs with a signiﬁcantly large overall chi-square statistic, we identi-
ﬁed the subtype that differed most markedly from the other subtypes
using pairwise comparisons.
The proportion of each TRAMwas also compared to its proportion in
a published comparison group of 5805 individualswithVF on aﬁrst-line
regimen containing a thymidine analog, zidovudine (AZT) or stavudine
(d4T), plus 3TC plus NVP or EFV using Fisher's Exact Test with an adjust-
ed p b 0.05 by Holm's adjustment.
2.3. Covariation of TDF-regimen Associated Mutations (TRAMs)
To identify patterns of covariation among the TRAMs, we calculated
the binomial phi correlation coefﬁcient for the simultaneous presence of
each pair of TRAMs in the same virus sequence. A signiﬁcant association
between TRAMswas deﬁned when twomutations occurred together in
virus sequences from ten ormore individuals and had a positive phi cor-
relation coefﬁcient with an adjusted p b 0.05 using the Holm's method.
To identify higher-level interactions among TRAMs, we used the R
package igraph to create an undirectedweighted network graph ofmuta-
tions fromthe adjacencymatrix of signiﬁcantly positively correlatedpairs.
This network contains edges between all signiﬁcantly correlated pairs of
mutations with edge lengths inversely correlated to the pair's phi coefﬁ-
cient. Mutational cliques were deﬁned as clusters of three or more muta-
tions that were each signiﬁcantly correlated with one another.
2.4. Mutational Predictors of Viral Load (VL)
To identify associations between TRAMs and theVL at the time of VF,
we ﬁrst performed univariate analyses for both mutational and non-
mutational covariates. The mutational covariates included number of
TRAMs, number of NRTI-associated TRAMs, number of NNRTI-associat-
ed TRAMs,M184V, K65R, K70E/Q/T/N, andK65R in combinationwith its
mutational partners (deﬁned asmutationswithwhich K65Rwas signif-
icantly correlated in our covariation analysis). The non-mutational co-
variates included the region (UIC vs. LMIC), NNRTI (EFV vs. NVP),
cytosine analog (3TC vs. FTC), and subtype. We then included in a mul-
tivariate linear regression analysis all mutational and non-mutational
covariates signiﬁcantly associated with VL in the univariate analysis.
To ensure the multivariate analysis was robust to study heterogeneity,
we included study as a random effect and performed a linear mixed
model using the R package lme4.
3. Results
3.1. Study Population
HIV-1 RT sequenceswere available from3413 individualswith VF on
a WHO-recommended ﬁrst-line TDF-containing regimen. Of these,
2873 (84.2%; 2873/3413) met study criteria. Five-hundred and forty
(15.8%; 540/3413) were excluded because their sequences contained
one or more TAMs (n = 523), were identical to another sequence in
the same study (n = 12), or contained evidence of APOBEC-mediated
G-to-A hypermutation (n = 5).
Seventy-nine percent (2262/2873) of study individuals received EFV
and 21% (611/2873) received NVP. Sixty-four percent (1826/2873) re-
ceived 3TC and 36% (1047/2873) received FTC. Seventy-two percent
(2071/2873) were from LMICs. The most common subtypes were C
(53%; 1524/2873), B (20%; 561/2873), CRF01_AE (13%; 365/2873), G
(5%; 135/2873), and A (4%; 110/2873). The median sample year was
2012 (Interquartile Range, IQR: 2010–2013). The duration of therapy
was available for 62% (1792/2873) of individuals. Among them, theme-
dian duration of therapy was 43.0 weeks (IQR: 21.0 to 83.0 weeks).
Table 1 summarizes the treatment regimens, location information,
and subtype distributions of the TDF study group and the ARV-naïve
and thymidine-analog control groups. Compared to the ARV-naïve con-
trol group, the TDF study group included a higher proportion of subtype
C infected individuals. Compared to the thymidine-analog control
group, the TDF study group was more recent, had a shorter duration
of therapy, and a slightly lower proportion of individuals from LMICs.
3.2. Identiﬁcation and Classiﬁcation of TDF-regimen Associated Mutations
(TRAMs)
Overall 640 RT mutations occurred in sequences from one or more
individuals. One hundred mutations (15.6%; 100/640) were signiﬁcant-
ly more common in the 2873 TDF recipients compared with the 50,803
ARV-naïve controls (adjusted p b 0.05; Fisher's Exact Test), and were at
least three times more common in the TDF recipients compared with
the ARV-naïve controls. Of these one hundred, 83 (13.0%; 83/640) oc-
curred in ten or more individuals and met criteria for being a TRAM
(Table 2). Supplementary Table 2 lists the 17 rare TRAMs that occurred
in fewer than 10 individuals. Seventy-ﬁve percent (2155/2873) of se-
quences encompassed codons 1 to 240 and 90% (2586/2873)
encompassed codons 30 to 240.
Of the 83 TRAMs, 16 (21%; 16/83) were established NRTI-associated
resistance mutations including A62V, K65R/N, T69deletion, K70E/Q/T/
N, L74V/I, V75M/I/L, Y115F, and M184V/I and 40 (48%; 40/83) were
established NNRTI-associated resistance mutations. The remaining 26
mutations included 12mutations at ﬁve positions previously associated
with NRTI therapy including S68D/G/N/R, T69I, W88S/C, T165L/V,
L228H/Q/R; ﬁve non-canonical TAMs including D67G, E203K, D218E,
and K219N/R;ﬁve uncommon previously undifferentiated RTI-associat-
edmutations (I31L/R, T58S, L109I, and K223E) and ﬁve previously unre-
ported mutations P4S/T, E28K, K46Q, and S163T.
The proportions of 53 TRAMswere not uniform among the ﬁvemost
common subtypes. For 13 TRAMs, themutation proportion was highest
with subtype C (Supplementary Table 3). For four, two, and two TRAMs,
the mutation proportion was highest for subtypes CRF01_AE, A and G,
respectively. For 28 and four TRAMs, themutation proportion was low-
est for subtype B and CRF01_AE, respectively. Themost notable ﬁndings
among the NRTI-associated TRAMs were an increased proportion of
K65R, S68N, and A62V in subtype C viruses, an increased proportion of
S68G in CRF01_AE viruses, and an increased proportion of K70E in sub-
type G viruses.
Table 3 compares the proportions of the TRAMs in this study com-
pared with their proportions in 5805 individuals who receiving a ﬁrst-
line thymidine analog-containing regimen. Twelve NRTI-associated
TRAMs – A62V, K65R/N, S68D/G/N, K70E/Q/T, L74I, V75L and Y115F,
and the established cytosine analog resistance mutation M184I, oc-
curred signiﬁcantly more commonly in the TDF group (Fig. 1). Five
NRTI-associated TRAMs occurred signiﬁcantly more commonly in the
thymidine analog group including V75I, T165L, M184V, D218E and
L228H. M184V occurred in 72.5% (4202/5799) of individuals in the thy-
midine analog group and in 48.7% (1400/2873) of individuals in the TDF
group (p b 0.001). M184I occurred in 9.4% (264/2873) of individuals in
the TDF group and in 2.2% (128/5799) of individuals in the thymidine
analog group (p b 0.001). Because M184V/I are established cytosine an-
alog resistance mutations known to increase TDF susceptibility, we ex-
cluded M184I from the list of TDF-selected TRAMs.
Although ten NNRTI-associated TRAMs occurred signiﬁcantly more
commonly in the TDF group and nine occurred signiﬁcantly more com-
monly in the thymidine analog group, the differences in the proportions
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of these TRAMs were often not large (Fig. 2). Among the unclassiﬁed
TRAMs, K46Q and E28K occurred more commonly in the TDF group
and in the thymidine analog group, respectively (Supplementary Fig. 1).
3.3. Covariation
Overall, 149 pairs of TRAMs co-occurred in ten or more individuals
and had signiﬁcant positive phi correlation coefﬁcients (adjusted p b
0.05). Thirty-ﬁve (23.5%; 35/149) pairs comprised two NRTI-associated
TRAMs, 30 (20.1%; 30/149) comprised twoNNRTI-associated TRAMs, 65
(43.6%; 65/149) comprised one NRTI- and one NNRTI-associated
TRAMs, and 19 (12.8%; 19/149) comprised at least one TRAM that had
not previously been associated with a speciﬁc RTI class.
The 35 pairs of signiﬁcantly correlated NRTI-associated TRAMs in-
cluded 21 of the 33 NRTI-associated TRAMs (Table 4). The NRTI-associ-
ated TRAMs most commonly correlated with other NRTI-associated
TRAMs were K65R (n = 10 pairs), M184V (n = 10 pairs), Y115F (n = 7
pairs), A62V (n = 5 pairs), S68N (n = 5 pairs), K70T (n = 5 pairs),
K70E (n = 4 pairs), S68G (n = 3 pairs), L74I (n = 3 pairs), and L228R
(n = 3 pairs). The most strongly correlated pairs (phi N 0.3) were K65R
+ A62V, K65R + S68N, K65R + S68G, K65R + Y115F, and K70E
+ L228R (Fig. 3). The largest clique included the following ﬁve TRAMs,
which were signiﬁcantly correlated with one another: M184V, K65R,
S68N, K70T and Y115F.
K65R was negatively correlated with both K70Q and K70E. There
were just two virus sequenceswith both K65R and K70Q but in each se-
quence both K65R and K70Q were present as electrophoretic mixtures.
There were 21 viruses with both K65R and K70E but in 16 both K65R
and K70E were present as electrophoretic mixtures and in ﬁve either
K65R or K70E was present as an electrophoretic mixture.
The 30 pairs of signiﬁcantly correlated NNRTI-associated TRAMs and
the 84 pairs comprising signiﬁcant correlations between NRTI- and
NNRTI-associated TRAMs are shown in the Supplementary Table 4,
and Supplementary Figs. 2 and 3.
3.4. Association of TDF-regimen Associated Mutations (TRAMs) With Viral
Load (VL)
VL at the time of VF was available in 32 of 51 studies including 50%
(1445/2873) of the TDF study population. The strongest predictor of
VL was being from an LMIC: VLswere signiﬁcantly higher in individuals
from LMICs (median 4.8 log10 copies/mL) compared with individuals
from UICs (median 3.9 log10 copies/mL; p b 0.001) (Supplementary
Table 5). Additional non-genotypic factors signiﬁcantly associated
with an increased VL at VF included receiving 3TC (compared with
FTC) and being infected with a non-subtype B virus. Signiﬁcant geno-
typic factors associated with an increased VL included the number of
TRAMs, the number of NRTI-associated TRAMs, the number of NNRTI-
associated TRAMs,M184V/I, K70mutations, andK65Rwith andwithout
one or more K65R partners (A62V, S68G/N/D, T69deletion, K70T, V75M
and Y115F). However, in ourmultivariate analysis only region (p b 0.004)
and number of NNRTI-associated TRAMs (p b 0.0001) were signiﬁcant
predictors of an increased VL.
4. Discussion
The earliest clinical trials of TDF-containing ﬁrst-line regimens were
performed in UICs (Gallant et al., 2006, 2004). In these trials, few indi-
viduals with VF developed RT mutations other than NNRTI-resistance
mutations and the cytosine analog resistance mutations M184V/I.
K65R was the most commonly occurring TDF-selected mutation, how-
ever, it rarely emerged in individuals undergoing frequent virological
monitoring in whom therapy was changed when VF was ﬁrst detected.
As TDF-containing regimens have become preferred for ﬁrst-line
therapy in LMICs (World Health Organization HIV/AIDS Programme,
2013), there have been an increasing number of studies of VF in individ-
uals receiving such a regimen who have undergone less frequent mon-
itoring than performed in clinical trials. We assembled sequences from
nearly 3000 individuals in these studies to characterize the spectrum
of RTmutations selected in individuals with VF on aWHO recommend-
ed TDF-containing ﬁrst-line regimen. By comparing these sequences to
those from a historical control population of ARV-naïve individuals, we
identiﬁed 83 TRAMs. By comparing the proportion of TRAMs in TDF re-
cipients to their proportions in a historical control population of thymi-
dine analog-treated individuals, we identiﬁed 12 TDF-selected TRAMs.
The 12 TDF-selected TRAMs included A62V, K65R/N, S68G/D/N,
K70E/Q/T, L74I, V75L, and Y115F. The most commonly occurring of
these were K65R (39.5%; 1134/2873), S68G/N (21.4%; 614/2873),
Y115F (11.9%; 343/2873), K70E/Q/T (10.9%; 312/2873), A62V (10.4%;
298/2873), and L74I (6.4%; 165/2873).
Table 1
Summary of individuals with virological failure (VF) on a ﬁrst-line TDF-containing regimen and two comparison groups: (i) antiretroviral therapy (ARV)-naïve individuals and (ii) indi-
viduals with VF on a ﬁrst-line thymidine analog-containing regimen according to treatment regimen, region and subtype.
Characteristics TDF-containing regimen (n = 2,873)
Comparison groups
ARV-naïve (n = 50,803)
Thymidine analog-containing regimen
(n = 5,805)
NRTs TDF + 3TC (64%), TDF + FTC (36%) None D4T + 3TC (64%), AZT + 3TC (36%)
NNRTIs EFV (79%), NVP (21%) None EFV (53%), NVP (47%)
Regimens TDF + 3TC + EFV (49%), TDF + FTC + EFV
(30%), TDF + 3TC + NVP (15%), TDF + FTC
+ NVP (6%)
None D4T + 3TC + EFV (35%), D4T + 3TC + NVP
(30%), AZT + 3TC + EFV (18%), AZT + 3TC +
NVP (17%)
Region LMIC (72%)
Sub-Saharan Africa (56%), South/Southeast
Asia (15%), Latin America (1%)
LMIC (49%)
Sub-Saharan Africa (23%), South/Southeast Asia
(13%), Latin America/Caribbean (11%), Former
Soviet Union (3%)
LMIC (88%)
Sub-Saharan Africa (65%), South/Southeast
Asia (19%), Latin America (2%), Former Soviet
Union (2%)
UIC (28%)
Europe (22%), North America (6%)
UIC (51%)
Europe (23%), North America (18%), Asia UICs
(10%)
UIC (12%)
Europe (6%), North America (6%), Asia UICs
(1%)
Subtype C (53%), B (20%), CRF01_AE (13%), G (5%), A
(4%), Other (6%)
B (53%), C (15%), CRF01_AG (11%), A (7%),
CRF02_AG (5%), Other (10%)
C (52%), CRF01_AE (16%), B (10%), A (7%),
CRF02_AG (5%), Other (11%)
Sample year, median
(IQR)
2012 (2010−2013) 2006 (2003–2008) 2008 (2006–2011)
Duration of therapy
available, median
(IQR) in weeks
63%, 43 (21–85) 39%, 97 (52–171)
Abbreviation: TDF – tenofovir disoproxil fumarate; FTC – emtricitabine; 3TC – lamivudine; AZT – zidovudine; D4T – stavudine; NVP – nevirapine; EFV – efavirenz; LMIC – low/middle-
income country; UIC – upper-income country.
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Table 2
Prevalence of TDF-regimen associated mutations (TRAMs) in ARV-naïve and in individuals receiving a WHO-recommended ﬁrst-line TDF-containing regimen.
Pos Cons AA
Drug
Class
Overall (%Rx)
n = 2,873
Overall (%ARV-Naive)
n = 50,803 Fold OR Fisher's exact test (adjusted p)
65 K R NRTI 39.5 0.1 489.1 803.6 0
106 V M NNRTI 19.8 0.0 559.9 707.8 0
115 Y F NRTI 11.9 0.0 303.2 344.1 0
184 M V NRTI 48.7 0.8 59.4 114.6 0
181 Y C NNRTI 23.0 0.5 44.9 58.0 0
190 G A NNRTI 13.3 0.4 35.3 40.5 0
103 K N NNRTI 38.5 1.8 21.3 34.0 0
184 M I NRTI 9.4 0.1 116.0 127.9 9.7E-295
225 P H NNRTI 8.7 0.1 71.6 78.1 5.1E-253
101 K E NNRTI 9.0 0.3 36.1 39.5 4.1E-230
100 L I NNRTI 7.2 0.1 114.3 123.0 4.1E-225
70 K E NRTI 6.6 0.0 241.2 256.6 1.6E-222
68 S N NRTI 8.1 0.3 30.7 33.4 7.6E-198
74 L I NRTI 5.7 0.1 78.8 83.7 7.1E-170
62 A V NRTI 10.4 1.0 10.8 11.9 1.7E-168
221 H Y NNRTI 6.6 0.2 34.6 37.0 2.9E-166
228 L R NRTI 5.5 0.1 45.7 48.4 9.0E-146
108 V I NNRTI 7.4 0.6 13.0 14.0 8.7E-132
227 F L NNRTI 4.6 0.1 58.3 61.0 1.6E-128
188 Y L NNRTI 4.7 0.1 39.5 41.3 7.2E-122
190 G S NNRTI 3.6 0.0 80.0 83.0 2.1E-106
98 A G NNRTI 5.2 0.3 17.3 18.2 3.8E-103
230 M L NNRTI 3.3 0.0 88.2 91.2 2.7E-96
68 S G NRTI 13.3 4.1 3.2 3.6 1.1E-77
70 K T NRTI 2.6 0.0 64.0 65.7 1.8E-74
90 V I NNRTI 8.6 2.0 4.2 4.5 3.8E-68
188 Y C NNRTI 2.4 0.0 63.3 64.8 2.5E-66
74 L V NRTI 2.6 0.1 29.9 30.6 1.9E-62
190 G E NNRTI 2.0 0.0 53.1 54.1 1.7E-53
67 D G NRTI 2.5 0.1 22.4 23.0 3.6E-53
203 E K NRTI 3.0 0.3 11.4 11.8 2.0E-48
46 K Q UNK 2.5 0.2 16.1 16.5 9.5E-47
75 V M NRTI 2.0 0.1 24.4 24.9 1.9E-44
70 K Q NRTI 1.6 0.0 66.3 67.3 9.9E-44
179 V D NNRTI 6.5 1.8 3.6 3.8 1.0E-42
68 S D NRTI 1.3 0.0 163.6 165.6 3.6E-40
190 G Q NNRTI 1.0 0.0 495.1 Inf 1.3E-33
101 K Q NNRTI 3.3 0.6 5.4 5.6 4.2E-32
232 Y H NNRTI 1.2 0.0 56.0 56.6 2.2E-30
101 K P NNRTI 1.1 0.0 48.6 49.1 8.3E-30
219 K R NRTI 1.5 0.1 16.5 16.8 8.6E-29
75 V I NRTI 1.5 0.1 15.6 15.8 4.7E-28
103 K S NNRTI 1.5 0.1 15.3 15.5 8.3E-28
106 V A NNRTI 1.2 0.0 31.6 32.0 1.3E-27
4 P S UNK 5.0 1.3 3.9 4.0 1.6E-25
101 K N NNRTI 1.0 0.0 39.5 39.8 8.8E-25
138 E G NNRTI 1.8 0.2 7.6 7.7 2.7E-22
69 T del NRTI 0.6 0.0 300.8 Inf 1.3E-19
181 Y V NNRTI 0.7 0.0 88.4 89.1 1.8E-19
188 Y H NNRTI 0.9 0.0 23.0 23.2 8.8E-19
88 W C NRTI 2.6 0.6 4.0 4.1 4.9E-18
31 I L RTI 1.5 0.2 7.8 7.9 1.3E-16
28 E K UNK 3.4 1.0 3.3 3.3 6.2E-16
109 L I RTI 0.8 0.0 17.7 17.8 1.5E-15
179 V E NNRTI 2.4 0.7 3.6 3.7 1.6E-14
228 L Q NRTI 1.0 0.1 9.5 9.6 2.8E-14
163 S T UNK 1.7 0.4 4.8 4.8 2.9E-14
101 K H NNRTI 0.6 0.0 56.6 56.9 3.9E-14
219 K N NRTI 0.9 0.1 11.3 11.4 4.5E-13
65 K N NRTI 0.7 0.0 21.0 21.1 6.6E-13
138 E Q NNRTI 0.8 0.1 14.4 14.5 6.9E-13
58 T S RTI 0.5 0.0 29.5 29.6 3.8E-11
139 T K NNRTI 1.5 0.3 4.3 4.4 1.2E-10
88 W S NRTI 1.0 0.2 6.4 6.5 5.3E-10
102 K N NNRTI 0.7 0.1 11.2 11.3 1.5E-09
181 Y I NNRTI 0.5 0.0 20.6 20.7 4.5E-09
234 L I NNRTI 0.5 0.0 18.3 18.4 1.4E-08
70 K N NRTI 0.5 0.0 14.0 14.0 3.2E-08
75 V L NRTI 1.1 0.2 4.5 4.6 6.2E-08
188 Y F NNRTI 0.5 0.0 14.6 14.6 9.3E-08
238 K T NNRTI 0.8 0.1 6.4 6.4 1.8E-07
223 K E RTI 0.5 0.0 11.3 11.3 2.8E-07
132 I L NNRTI 0.6 0.1 8.6 8.6 4.6E-07
(continued on next page)
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Because most of the additional TDF-selected TRAMs usually oc-
curred in combination with K65R, the overall prevalence of one or
more of the 12 TDF-selected TRAMs in this study was only slightly
higher than the overall prevalence of K65R/N and/or K70E/G/Q in in-
dividuals with VF on a TDF-containing ﬁrst-line WHO recommended
regimen (54% vs. 47%; 1551/2873 vs. 1350/2873). However,
previously published data outlined below suggest that these
additional mutations may confer greater reductions in TDF
susceptibility than K65R alone.
Several of the 12 TDF-selected TRAMshave been previously associat-
ed with K65R, TDF selection pressure, or reduced in vitro TDF
susceptibility. Speciﬁcally, A62V and S68G have been reported to
Table 2 (continued)
Pos Cons AA
Drug
Class
Overall (%Rx)
n = 2,873
Overall (%ARV-Naive)
n = 50,803 Fold OR Fisher's exact test (adjusted p)
228 L H NRTI 1.2 0.3 3.6 3.7 1.3E-06
69 T I NRTI 0.6 0.1 6.8 6.8 2.9E-06
138 E K NNRTI 0.7 0.1 5.5 5.6 3.1E-06
165 T L NRTI 0.4 0.0 11.5 11.5 4.9E-05
4 P T UNK 1.4 0.5 3.1 3.1 1.8E-04
165 T V NRTI 0.4 0.1 7.3 7.3 5.2E-04
31 I R RTI 0.4 0.1 7.3 7.3 1.5E-03
218 D E NRTI 0.6 0.1 4.4 4.4 2.8E-03
68 S R NRTI 0.4 0.1 5.7 5.7 9.8E-03
139 T R NNRTI 0.5 0.1 4.2 4.2 2.9E-02
83 TRAMs were listed in the order of the signiﬁcance estimated by Fisher's exact test. Estimated odds ratios (OR) by Fisher's exact test and their p-values adjusted by Holm's method are
shown. Each TRAM was classiﬁed to NRTI-associated, NNRTI-associated or undifferentiated (in the DrugClass; see Methods).
Abbreviation: TDF – tenofovir disoproxil fumarate; ARV- antiretroviral; Cons - consensus amino acid (deﬁned in the Methods); RTI - reverse transcriptase inhibitor; NRTI - nucleos(t)ide
RTI; NNRTI - non-NRTI; UNK - undifferentiated.
Table 3
Comparison of proportion of each TDF-regimen associatedmutations (TRAMs) between in individuals receiving a TDF-containing ﬁrst-line and individuals receiving an AZT/D4T-contain-
ing ﬁrst-line regimen.
Pos Cons AA DrugClass
TDF (%)
n = 2,837
AZT/D4T (%)
n = 5,805 Fold OR Fisher's exact test (adjusted p)
65 K R NRTI 39.5 3.6 11.1 17.6 0
115 Y F NRTI 11.9 0.6 19.2 21.7 7.5E-125
184 M V NRTI 48.7 72.5 0.7 0.4 5.6E-101
68 S N NRTI 8.1 0.4 18.8 20.4 5.8E-83
70 K E NRTI 6.6 0.5 13.3 14.2 5.5E-61
184 M I NRTI 9.4 2.2 4.2 4.6 2.4E-45
100 L I NNRTI 7.2 1.5 4.7 5.0 6.0E-38
74 L I NRTI 5.7 1.5 3.8 4.0 1.7E-24
70 K T NRTI 2.6 0.3 10.2 10.5 2.1E-21
46 K Q UNK 2.5 0.3 9.5 9.7 2.5E-19
68 S G NRTI 13.3 7.0 1.9 2.0 1.2E-18
70 K Q NRTI 1.6 0.1 30.3 30.7 7.9E-17
62 A V NRTI 10.4 5.3 2.0 2.1 2.1E-15
106 V M NNRTI 19.8 13.4 1.5 1.6 1.5E-12
68 S D NRTI 1.3 0.1 18.7 18.9 2.2E-12
218 D E NRTI 0.6 2.8 0.2 0.2 4.1E-12
190 G E NNRTI 2.0 0.4 5.5 5.6 3.5E-11
228 L H NRTI 1.2 3.6 0.3 0.3 2.6E-10
75 V I NRTI 1.5 4.0 0.4 0.4 6.8E-09
238 K T NNRTI 0.8 2.8 0.3 0.3 1.0E-08
179 V D NNRTI 6.5 3.7 1.8 1.8 6.4E-07
132 I L NNRTI 0.6 2.1 0.3 0.3 7.0E-07
165 T L NRTI 0.4 1.7 0.2 0.2 3.9E-06
139 T R NNRTI 0.5 1.6 0.3 0.3 6.7E-05
181 Y C NNRTI 23.0 18.7 1.2 1.3 1.6E-04
31 I L RTI 1.5 3.3 0.5 0.5 2.5E-04
190 G Q NNRTI 1.0 0.2 4.0 4.1 5.5E-04
190 G A NNRTI 13.3 16.9 0.8 0.8 6.2E-04
101 K H NNRTI 0.6 1.6 0.4 0.3 1.1E-03
138 E Q NNRTI 0.8 1.9 0.4 0.4 1.3E-03
221 H Y NNRTI 6.6 9.3 0.7 0.7 1.4E-03
138 E G NNRTI 1.8 0.8 2.3 2.3 2.7E-03
98 A G NNRTI 5.2 7.4 0.7 0.7 4.2E-03
190 G S NNRTI 3.6 2.2 1.7 1.7 5.6E-03
75 V L NRTI 1.1 0.4 2.8 2.9 8.9E-03
108 V I NNRTI 7.4 9.9 0.8 0.7 9.0E-03
28 E K UNK 3.4 5.3 0.6 0.6 9.6E-03
179 V E NNRTI 2.4 1.3 1.8 1.9 1.5E-02
65 K N NRTI 0.7 0.2 3.5 3.5 3.4E-02
188 Y C NNRTI 2.4 1.4 1.7 1.7 4.8E-02
Proportion of each of the TRAMs was compared with those receiving AZT/D4T containing ﬁrst-line regimens. The comparisons were performed using Fisher's exact test. Estimated odds
ratios (OR) by Fisher's exact test and their p-values adjusted by Holm's method are shown. TRAMs were shown in the order of their p values. Abbreviation: TDF – tenofovir disoproxil
fumarate; AZT – zidovudine; D4T – stavudine; RTI - reverse transcriptase inhibitor; NRTI - nucleos(t)ide RTI; NNRTI - non-NRTI; UNK - undifferentiated.
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improve the replication of viruses with K65R (Svarovskaia et al., 2008).
S68N has been selected in vitro by TDF and shown to further reduce TDF
susceptibility when present with K65R (Margot et al., 2006). Y115F, al-
though it is primarily an abacavir (ABC)-resistance mutation, has been
selected in vitro by TDF and shown to reduce TDF susceptibility
(Margot et al., 2006; Melikian et al., 2012; Stone et al., 2004). L74I,
which is also primarily an ABC-resistance mutation, has been reported
to be selected by TDF (Wirden et al., 2009).
Fig. 1. Prevalence of nucleoside RT inhibitor (NRTI)-associated tenofovir disoproxil fumarate (TDF)-regimen associated mutations (TRAMs) in 2,873 individuals with virological failure
(VF) on a TDF-containing 1st-line regimen (a); in 5,805 individuals with VF on a thymidine analog-containing 1st-line regimen (b); and in 50,803 antiretroviral (ARV)-naive
individuals (c). NRTI TRAMs that were signiﬁcantly more common in individuals receiving a TDF-containing regimen compared to in individuals receiving a thymidine analog-
containing regimen are shown in blue. NRTI TRAMs that were signiﬁcantly more common in individuals receiving a thymidine analog-containing regimen compared to in individuals
receiving a TDF-containing regimen are shown in brown.
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K70E/G/Q/N/T have previously been reported to occur rarely in indi-
viduals receiving d4T, ABC, and TDF-containing regimens and to be as-
sociated with slightly reduced susceptibility to these NRTIs (Tang et
al., 2013; Delaugerre et al., 2008; Sluis-Cremer et al., 2007; Hachiya et
al., 2011). In this study, we observed a signiﬁcant association with a
TDF-containing regimen for each of thesemutations. Of these, K70G oc-
curred in just four individuals (Supplementary Table 2). K70E has been
reported to rarely occur in combination with K65R because of the
Fig. 2. Prevalence of non-nucleoside RT inhibitor (NRTI)-associated tenofovir disoproxil fumarate (TDF)-regimen associated mutations (TRAMs) in 2,873 individuals with virological
failure (VF) on a TDF-containing 1st-line regimen (a); in 5,805 individuals with VF on a thymidine analog-containing 1st-line regimen (b); and in 50,803 antiretroviral (ARV)-naive
individuals (c). NNRTI TRAMs that were signiﬁcantly more common in individuals receiving a TDF-containing regimen compared to in individuals receiving a thymidine analog-
containing regimen are shown in blue. NNRTI TRAMs that were signiﬁcantly more common in individuals receiving a thymidine analog-containing regimen compared to in individuals
receiving a TDF-containing regimen are shown in brown.
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reduced replication ﬁtness when both mutations occur in the same
virus (Kagan et al., 2007). We conﬁrmed this observation and demon-
strated that the same antagonistic interaction exists between K65R
and K70Q. Their negative association and the high proportion of
mixed bases in cases where they did co-occur suggest they rarely
occur in the same virus genomes. The same antagonistic interaction
was not observed between K65R and K70T/N.
Of the cytosine analog resistance mutations, M184V occurred more
commonly in the thymidine analog group whereas M184I occurred
more commonly in the TDF group. M184I has been reported to often
precede the development ofM184V among individuals receiving a cyto-
sine analog (Back et al., 1996). In these individuals, M184V eventually
replaces M184I because its replication capacity is less attenuated than
that of M184I. We speculate that M184I occurred more commonly in
the TDF group compared with the thymidine analog group because
the duration of therapywas shorter in the TDF group – possibly because
of more frequent virological monitoring in this somewhat more recent
cohort. Consistent with this is the fact that the thymidine analog cohort
contained a higher proportion of individuals from LMICs (88% vs. 72%;
5082/5805 vs. 2071/2873) and preceded the TDF cohort by a median
of four years (2008 vs. 2012) (Table 1).
The association between subtypes and TRAMs was most notable for
an increased proportion of several TRAMs in subtype C and less com-
monly CRF01_AE, and G and a decreased proportion of many TRAMs
in subtype B viruses. However, this analysis is likely to be confounded
by the fact that fewer number of viruses was available for subtype G,
A and CRF01_AE and that subtype B was more common in the UICs
where virological monitoring has been frequent and the time on a reg-
imen following VF was likely to have been shorter.
The established TDF-resistancemutations K65R and K70E have been
shown to attenuate virus replication in vitro and in animal models
(Miller et al., 2002; Van Rompay et al., 2007; White et al., 2002;
Sluis-Cremer et al., 2007). To determine whether these and other TDF-
selected TRAMs are associated with reduced VL and a potentially re-
duced risk of TDF resistance transmission, we attempted to correlate
speciﬁc TDF-selected TRAMs with VL at the time of VF. However, this
analysis was limited by the availability of VL data in only half of study
individuals and the likely differences in the frequency of viral loadmon-
itoring in different study populations. Although LMIC region and the
number of NNRTI-associated TRAMs appeared to be independently as-
sociatedwith an increased VL at VF in ourmultivariate analysis, the lim-
ited availability of VL data prevents us from drawing any conclusions
about the potential transmissibility of viruses containing TDF-selected
TRAMs.
The widely used list of DRMs for the surveillance of transmitted
drug-resistance (SDRMs) was developed at a time when the number
of available sequences from individuals with VF on a ﬁrst-line TDF-con-
taining regimen was low (Bennett et al., 2009). Of the 12 TDF-selected
TRAMs, the SDRM list includes the established TDF-resistance muta-
tions K65R and K70E, and the established ABC-resistance mutations
L74I and Y115F. The remaining eight TDF-selected TRAMs are not on
the SDRM list. Two of these TRAMs are polymorphic and are therefore
not SDRM candidates for monitoring transmitted drug-resistance:
S68G occurs in 1.6% to 6.6% of ARV-naïve individuals depending on sub-
type and A62V is the consensus residue in subtype A viruses in the For-
mer Soviet Union countries (Rhee et al., 2003). The remaining six TDF-
selected TRAMs, K65N, S68N/D, K70Q/T, and V75L are nonpolymorphic
and should be considered for possible addition to the SDRM list.
Table 4
Signiﬁcantly correlated NRTI-associated TDF-regimen associated mutations (TRAMs) pairs.
Mut1 Mut2 Mut1% Mut2% Phi Mut1+ Mut2 Mut1 alone Mut2 alone Neither Adjusted p
K70E L228R 6.6 5.5 0.38 72 86 119 2596 0
A62V K65R 10.4 39.5 0.35 268 866 30 1709 0
K65R S68N 39.5 8.1 0.35 225 8 909 1731 0
K65R S68G 39.5 13.3 0.32 301 80 833 1659 0
K65R Y115F 39.5 11.9 0.31 277 66 857 1673 0
K70T S68G 2.6 13.3 0.29 56 325 20 2472 0
M184V K65R 48.7 39.5 0.27 740 394 660 1079 0
A62V S68N 10.4 8.1 0.25 84 149 214 2426 0
K70E D67G 6.7 2.5 0.25 32 39 159 2642 0
M184V K70E 48.7 6.6 0.24 178 13 1222 1460 0
M184V L74I 48.7 5.7 0.24 159 6 1241 1467 0
M184V A62V 48.7 10.4 0.22 243 55 1157 1418 0
M184V S68N 48.7 8.1 0.2 193 40 1207 1433 0
M184V Y115F 48.7 11.9 0.2 258 85 1142 1388 0
K65R K70T 39.5 2.6 0.19 73 3 1061 1736 0
S68G T69I 13.3 0.6 0.19 17 1 364 2489 0
K70T S68N 2.6 8.1 0.16 26 207 50 2590 0
L74V Y115F 2.6 11.9 0.15 32 311 44 2486 2.9E-12
M184V L228R 48.7 5.5 0.15 127 31 1273 1442 2.9E-12
K65R S68D 39.5 1.3 0.13 35 2 1099 1737 1.0E-08
K70E K219R 6.6 1.5 0.13 14 30 177 2652 1.0E-08
K70T Y115F 2.6 11.9 0.12 27 316 49 2481 4.1E-07
L74I Y115F 5.7 11.9 0.12 45 298 120 2410 4.1E-07
Y115F S68N 11.9 8.1 0.12 59 174 284 2356 4.1E-07
M184I K65R 9.4 39.5 0.12 157 977 112 1627 4.1E-07
M184V K70Q 48.7 1.6 0.11 41 4 1359 1469 1.2E-05
A62V V75I 10.4 1.5 0.1 15 29 283 2546 2.7E-04
K70Q L74I 1.6 5.7 0.1 11 154 34 2674 2.7E-04
M184V L74V 48.7 2.6 0.1 60 16 1340 1457 2.7E-04
K65R T69del 39.5 0.6 0.1 17 0 1116 1738 2.7E-04
A62V L228Q 10.4 1.0 0.09 11 19 287 2556 4.5E-03
K65R V75M 39.5 2.0 0.09 40 18 1094 1721 4.5E-03
V75I Y115F 1.5 11.9 0.09 15 328 29 2501 4.5E-03
M184V K70T 48.7 2.6 0.09 57 19 1343 1454 4.5E-03
K219R L228R 1.5 5.5 0.09 10 148 34 2681 4.5E-03
Pairs of NRTI TRAMs co-occurring in ten or more sequences with a signiﬁcant Phi correlation coefﬁcient are listed in the order of their p values (an adjusted p b 0.05 by Holm's method).
Mut1 +Mut2 contains number of sequences containing Mut1 and Mut2. Mut1 Alone contains number of sequences containing Mut1 but not Mut2. Mut2 Alone contains number of se-
quences containing Mut2 but not Mut1. Neither contains number of sequences containing neither of Mut1 or Mut2.
Abbreviation: TDF – tenofovir disoproxil fumarate; NRTI - nucleos(t)ide reverse transcriptase inhibitor.
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In conclusion, this study shows that the spectrum of TDF-selected
mutations extends beyond K65R/N and K70E/G/Q. Several of the addi-
tional TDF-selected mutations are nonpolymorphic mutations that are
currently not considered surveillance DRMs yet may be important for
monitoring TDF-associated transmitted drug-resistance (Bennett et al.,
2009). Additionally, the clinical signiﬁcance of several mutations that
occurred commonly in combination with K65R including A62V, S68G/
N/D, L74I, V75L and Y115F requires further phenotypic and clinical
studies to better understand their effects on both TDF and the newly de-
veloped prodrug tenofovir alafenamide (TAF) (Margot et al., 2016).
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